The concomitant utilization of oxycodone HCl with all cytochrome P450 3A4 inhibitors might lead to a rise in oxycodone plasma concentrations, which could raise or lengthen adverse reactions and could trigger potentially fatal respiratory depression. On top of that, discontinuation of the concomitant